In our present study, Kaplan-Meier survival analysis showed that pancreatic cancer patients with elevated levels of TAMs (indicated by the expression of CD163, CD204, and CD206) or eEF2K, as well as those expressing both CD68 and eEF2K, have poorer overall survival. This evidence concerns the gene MSR1 and familial pancreatic carcinoma.